TY - JOUR
T1 - Intrahepatic infusional therapy for metastatic ovarian carcinoma
AU - Malone, John M.
AU - Gershenson, David M.
AU - Carrasco, C. Humberto
AU - Charnsangavej, Chusilp
AU - Copeland, Larry J.
AU - Larson, Dale M.
AU - Kavanagh, John J.
AU - Edwards, Creighton L.
AU - Wallace, Sidney
PY - 1987/6/1
Y1 - 1987/6/1
N2 - Twenty‐four women with ovarian carcinoma that had metastasized to the liver were treated with intrahepatic infusional therapy. No consistent drug regimen was used. There were no complete responders; however, 33% had a partial response. All responses were noticed after the first course of therapy. The median length of response was 6.3 months. The median survival from the time of the first hepatic infusion was 7.5 months for all patients. In this series, there were two treatment‐related deaths, one secondary to the chemotherapy, the other to improper catheter placement. Because of the multiplicity of chemotherapy regimens employed, no definite conclusions can be made concerning the efficacy of intrahepatic infusional therapy for metastatic ovarian carcinoma. It is suggested that its future use be restricted to patients with disease limited to the liver and who are being treated according to a study protocol.
AB - Twenty‐four women with ovarian carcinoma that had metastasized to the liver were treated with intrahepatic infusional therapy. No consistent drug regimen was used. There were no complete responders; however, 33% had a partial response. All responses were noticed after the first course of therapy. The median length of response was 6.3 months. The median survival from the time of the first hepatic infusion was 7.5 months for all patients. In this series, there were two treatment‐related deaths, one secondary to the chemotherapy, the other to improper catheter placement. Because of the multiplicity of chemotherapy regimens employed, no definite conclusions can be made concerning the efficacy of intrahepatic infusional therapy for metastatic ovarian carcinoma. It is suggested that its future use be restricted to patients with disease limited to the liver and who are being treated according to a study protocol.
UR - http://www.scopus.com/inward/record.url?scp=0023179551&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023179551&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(19870601)59:11<1866::AID-CNCR2820591104>3.0.CO;2-#
DO - 10.1002/1097-0142(19870601)59:11<1866::AID-CNCR2820591104>3.0.CO;2-#
M3 - Article
C2 - 3567850
AN - SCOPUS:0023179551
SN - 0008-543X
VL - 59
SP - 1866
EP - 1869
JO - Cancer
JF - Cancer
IS - 11
ER -